Compare Msci Inc (MSCI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Novartis AG — how do they compare? Msci Inc trades at $561.5 (market cap $45.51B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 6.4× Msci Inc's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| MSCI | NVS | |
|---|---|---|
Market Cap | $45.51B | $290.25B |
Sector | Financials | Health |
52-Week High | $643.83 | $168.62 |
52-Week Low | $511.84 | $113.50 |
Enterprise Value | $51.67B | $330.27B |
Dividend Yield | 1.31% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI is trading at $561.74, down 10.64% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The company reported Q2 2026 EPS of $4.94, exceeding estimates of $4.90, driven by recurring subscription growth and ETF-linked AUM. Technical indicators show a bullish trend with key support at $606, while valuation ratios remain elevated with a P/E of 35.7. Recent strategic partnerships with UBS and the acquisition of First Street enhance its private markets and climate risk capabilities.
Outlook remains positive with 73% analyst buy ratings and a $725.44 consensus price target, implying 29% upside. Risks include high debt levels ($4.51B) and competitive pressures in financial data services. The stock offers growth potential through innovation and market expansion, but investors should monitor execution on strategic initiatives and margin sustainability amid economic uncertainties.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
